Commonwealth Bank of Australia’s BioMarin Pharmaceuticals BMRN Stock Holding History

Commonwealth Bank of Australia’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-472	Closed	-$39K	–	139
2019 Q2	$39K	Buy	472 +122	+35%	+$10.4K	﹤0.01%	1001
2019 Q1	$30K	Hold	350	–	–	﹤0.01%	998
2018 Q4	$29K	Buy	350 +116	+50%	+$11K	﹤0.01%	994
2018 Q3	$21K	Sell	234 -100	-30%	-$9.98K	﹤0.01%	1057
2018 Q2	$30K	Buy	334 +164	+96%	+$14.4K	﹤0.01%	705
2018 Q1	$13K	Hold	170	–	–	﹤0.01%	730
2017 Q4	$13K	Sell	170 -2	-1%	-$174	﹤0.01%	749
2017 Q3	$14K	Sell	172 -804	-82%	-$71K	﹤0.01%	733
2017 Q2	$87K	Buy	976 +172	+21%	+$15.6K	﹤0.01%	732
2017 Q1	$70K	Buy	804 +123	+18%	+$10.9K	﹤0.01%	757
2016 Q4	$57K	Sell	681 -130	-16%	-$11.2K	﹤0.01%	748
2016 Q3	$76K	Hold	811	–	–	﹤0.01%	686
2016 Q2	$63K	Sell	811 -240	-23%	-$20.4K	﹤0.01%	700
2016 Q1	$87K	Buy	1,051 +259	+33%	+$21.1K	﹤0.01%	651
2015 Q4	$83K	Buy	792 +159	+25%	+$16.6K	﹤0.01%	666
2015 Q3	$66K	Buy	633 +208	+49%	+$27.8K	﹤0.01%	695
2015 Q2	$58K	Sell	425 -175	-29%	-$21.7K	﹤0.01%	689
2015 Q1	$75K	Sell	600 -200	-25%	-$21.2K	﹤0.01%	621
2014 Q4	$72K	Sell	800 -5,000	-86%	-$416K	﹤0.01%	621
2014 Q3	$419K	Sell	5,800 -200	-3%	-$13.1K	0.01%	628
2014 Q2	$373K	Sell	6,000 -49,183	-89%	-$2.97M	0.01%	623
2014 Q1	$3.76M	Sell	55,183 -1,380	-2%	-$102K	0.02%	512
2013 Q4	$3.98M	Sell	56,563 -240	-0.4%	-$16.3K	0.03%	480
2013 Q3	$4.1M	Sell	56,803 -5,007	-8%	-$333K	0.03%	441
2013 Q2	$3.44M	Buy	+61,810	New	+$3.85M	0.03%	462

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Commonwealth Bank of Australia's BMRN Position: Q3 2019 in Review

Commonwealth Bank of Australia sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 472 shares — an estimated $39K sold.

Commonwealth Bank of Australia first reported a position in BMRN in Q2 2013 and held it in 25 quarters. The position peaked at $4.1M in Q3 2013. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Commonwealth Bank of Australia reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Commonwealth Bank of Australia sold 472 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $39K.
Commonwealth Bank of Australia first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 25 quarters.
Commonwealth Bank of Australia's BioMarin Pharmaceuticals position peaked at $4.1M in Q3 2013.
437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Commonwealth Bank of Australia's 13F filing for Q3 2019.